Company: XOMAP
Filing Date: 2025-10-02
Form Type: SC TO-T/A
Source: 0001193125-25-228454
Chunk: 1

Company: XOMA Royalty Corp
Filing Date: 2025-10-02
Form: SC TO-T/A
Chunk 1
---
 purchase all of the issued and outstanding common shares, with a nominal value of €0.12 per share
(“”), in the capital of LAVA Therapeutics N.V., a public limited liability company (naamlozevennootschap) organized under the laws of the Netherlands, having its corporate seat (statutairezetel) in Utrecht, the Netherlands, registered with the Dutch trade register under number 65335740 (“”), all upon the terms and subject to the conditions described in the Offer to Purchase, dated August 15,
2025 (together with any subsequent amendments or supplements thereto, the “”) filed herewith and in the related Letter of Transmittal, copies of which are attached hereto as exhibits (a)(1)(A) and (a)(1)(B),
respectively. The Offer is being made pursuant to the Share Purchase Agreement, dated as of August 3, 2025 (together with any amendments or supplements thereto, the “”), among LAVA and Purchaser, a copy of
which is filed as Exhibit (d)(1) hereto and incorporated herein by reference with respect to Items 4 through 11 of this Schedule TO.

Except as otherwise set forth in this Amendment, all terms of the Offer and all other disclosures set forth in the Schedule TO and the
Exhibits thereto remain unchanged and are hereby expressly incorporated into this Amendment by reference. This Amendment should be read together with the Schedule TO. Capitalized terms used and not otherwise defined in this Amendment shall have
the meanings assigned to such terms in the Offer to Purchase.

The Schedule TO is hereby amended and supplemented as follows:

ITEMS 1 THROUGH 9 AND 11

The Offer to
Purchase and Items 1 through 9 and 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented to include the following:

“Extension of the Offer

On October 2, 2025, Purchaser extended the Expiration Date of the Offer until one minute after 11:59 p.m. Eastern Time on October 17,
2025. The press release announcing the extension of the Offer is filed as Exhibit (a)(5)(B) hereto and is incorporated herein by reference.

AMENDMENTS TO THE OFFER TO PURCHASE AND THE OTHER EXHIBITS

The information set forth in the Offer to Purchase (Exhibit (a)(1)(A)), Form